

# AbsolutePRP® and PurePRP®


FDA Cleared Platelet-Rich Plasma Kits

Clinical grade PRP, backed by data




Platelet Rich Plasma (PRP) consists of a concentrated solution of platelets, (PLTs) growth factors, signaling molecules, and plasma proteins that play vital roles in orchestrating a healing response.

PRP is injected directly into the injured area, stimulating a healing cascade to treat acute injury, inflammation and/or chronic degenerative disease. Platelets store a vast array of growth factors which are released at the site of injury through cell signaling and local activation.







# **APPLICATION RECOMMENDATIONS** (Tip Sheets by indication available)

## Osteoarthritis (OA) of Joints

- Knee<sup>7,8</sup>
- Hip<sup>2,5</sup>
- Shoulder<sup>23</sup>
- Hand<sup>9</sup>
- Ankle<sup>6</sup>

#### Spine

- Degenerative Disc Disease<sup>21</sup>
- Facet Joint OA<sup>15</sup>
- SI Joint Dysfunction<sup>13</sup>

## Tissues (Ligaments & Tendons)

- Tennis / Golfers Elbow (Lateral / Medial epicondylitis)<sup>18,19</sup>
- Acetabular Hip Labrum Tear<sup>20</sup>
- Bursitis/Greater Trochanteric Pain Syndrome/Gluteus Medius and Minimus Tendinopathy 1,3,17
- Tendonitis / Tendonosis<sup>29,30</sup>
- Ankle Tendinopathy<sup>4</sup>
- Subacromial Impingement Syndrome<sup>22</sup>
- Partial Thickness Rotator Cuff Tear<sup>23</sup>

#### Bone

- Non-Union / Accelerated Bone Healing<sup>25</sup>
- Subchondral Edema<sup>31</sup>
- Subchondral Bone (often in conjunction with joint injection)<sup>24,27</sup>

#### **BENEFITS**

## Flexibility

- Variety of kit sizes (20mL, 30mL, 60mL, 120mL)
- PLT dose and PRP volume flexible to indication treated
  Protocol A: Neutrophil-Poor
  Protocol B: Neutrophil-Rich
- One kit, two protocols (Neutrophil-Rich and Neutrophil-Poor)
- PRP centrifuge can also spin Bone Marrow Concentrates, Plasma Concentrates (α-2-M) and Adipose grafts (all FDA cleared 510k kits)

## Safe + Therapeutic

- Closed system
- Highest PLT dose on the market
- Made in the USA
- No need for laminar flow hood











# PERFORMANCE INFORMATION

SUMMARY: Hematology of Products (Mean ± Standard Deviation)

| Platform      | WBC x 10 <sup>6</sup> /mL | MC x 10 <sup>6</sup> /mL | GRAN x 106/mL    | PLT x 10 <sup>6</sup> /mL | HCT %            |
|---------------|---------------------------|--------------------------|------------------|---------------------------|------------------|
| PurePRP II    | <b>10.7</b> ± 3.2         | <b>9.8</b> ± 3.0         | <b>0.9</b> ± 0.4 | <b>1,293</b> ± 362        | <b>1.1</b> ± 0.4 |
| Harvest Clear | <b>1.4</b> ± 1.2          | <b>1.0</b> ± 1.3         | <b>0.1</b> ± 0.1 | <b>1,003</b> ± 307        | <b>0.1</b> ± 0.1 |
| Arthrex Angel | <b>5.9</b> ± 1.4          | <b>4.8</b> ± 1.6         | <b>1.2</b> ± 1.0 | <b>859</b> ± 231          | <b>2.8</b> ± 0.3 |

MC= Lymphocytes + Monocytes; GRAN = Granulocytes; PLT = Platelet

| Platform      | PDGF AB (pg/mL)        | TGF-β (pg/mL)          | VEGF (pg/mL)     | SDF-1a (pg/mL)     |
|---------------|------------------------|------------------------|------------------|--------------------|
| PurePRP II    | <b>68,194</b> ± 12,398 | <b>75,546</b> ± 21,491 | <b>813</b> ± 811 | <b>3,418</b> ± 537 |
| Harvest Clear | <b>55,860</b> ± 18,013 | <b>58,505</b> ± 18,048 | <b>689</b> ± 697 | <b>3,113</b> ± 610 |
| Arthrex Angel | <b>39,714</b> ± 11,248 | <b>41,886</b> ± 12,794 | <b>387</b> ± 293 | <b>2,771</b> ± 661 |



|   | AbsolutePRP                           | PurePRP  | Arthrex Angel | Harvest Clear | Magellan/ISTO |
|---|---------------------------------------|--|---------------|---------------|---------------|
| Hematocrit %                            | Protocol A: <1%<br>Protocol B: 42-46% | Protocol A: <1%<br>Protocol B: 5%                          | Variable      | Less than 1%  | 7.8%          |
| Platelet<br>Concentration<br>x Baseline | Protocol A: 3.5x<br>Protocol B: 5.0x  | Protocol A: 3x-28x<br>Protocol B: 3x-28x                   | 4x            | 5x            | 6x            |
| Platelet Yield                          | 70%-96%                               | >80%   | 49%           | 62%           | 63%           |
| Granulocyte<br>Reduction                | Protocol A: 98%<br>Protocol B: 13-23% | Protocol A: 98%<br>Protocol B: 23%                         | 97%           | 100%          | 74%           |
| Processing Time                         | Protocol A: 1min<br>Protocol B: 5min  | Protocol A & B:<br>1 min first spin +<br>5 min second spin | 15 min        | 14 min        | 12-17 min     |

Reference: BSR lab, Robert Mandle, 2015, White paper Data on file https://www.plymouthmedical.com/resources



## **PUBLICATIONS**

For a full list of publications please visit the following link: www.plymouthmedical.com/educationalreferences or scan the QR code to the left.

#### Regulatory: BK 050055

FDA Clearance 510 (k) Class II Medical Device, which is designed to be used for the safe and rapid preparation of autologous platelet rich plasma (PRP) from a small sample of blood at the patients point of care.

TEL - 888.392.5076 FAX - 888.392.1455 WEB - PLYMOUTHMEDICAL.COM PLYMOUTH MEDICAL 135 PLYMOUTH ST, SUITE 410 BROOKLYN, NY 11201